Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Japanese Hep C Boosts Gilead Sciences (GILD) in the Qtr - Baird
February 3, 2016 7:20 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and $135 price target on Gilead Sciences (NASDAQ: GILD) following Q4 results which beat on Japanese Hep C.
Skorney commented, "Gilead delivered another top- and bottom-line beat, driven by Japanese Hep C sales. We... More
Gilead's (GILD) Increased Unit Sales Tempered By Lower Prices - Oppenheimer
February 3, 2016 7:11 AM ESTOppenheimer analyst, Wendy Lam, trimmed her price target on Gilead Sciences (NASDAQ: GILD) as the increasing volume of Harvoni will be offset by reductions in price. One bright note was the strong start to HIV as Genvoya generated $44B in sales. PT is cut to $120 from $124 but maintaining the Outperform rating.
GILD reported 4Q15 revenue of $8.5B and non-GAAP EPS of $3.32, topping Street consensus estimates of $8.2B and $3.00. However, GILD's 2016 guidance on net product sales of... More
Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; Adds $12B to Stock Buyback Plan
February 2, 2016 4:03 PM ESTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.
The dividend will be payable on March 30, 2016, to stockholders of record on March 16, 2016, with an ex-dividend date of March 14, 2016.
The annual yield on the dividend is 2.1 percent.
In addition the Board authorized an increase of 4 cents (ten percent) in the companys quarterly dividend program,... More
Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; Adds $12B to Stock Buyback Plan
February 2, 2016 4:03 PM ESTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.
The dividend will be payable on March 30, 2016, to stockholders of record on March 16, 2016, with an ex-dividend date of March 14, 2016.
The annual yield on the dividend is 2.1 percent.
In addition the Board authorized an increase of 4 cents (ten percent) in the companys quarterly dividend program,... More
